Inozyme Pharma halts infant ENPP1/ABCC6 trial of INZ-701 after enrolling 9
The ENERGY study was stopped by the sponsor for program reasons unrelated to safety, with final enrollment at 9 infants.
ClinicalTrials.gov
Latest
Thursday, October 15
FDA approves efficacy supplement for UCB's Zilbrysq
The agency cleared supplement 15 for the zilucoplan sodium injection, according to an FDA drug approval letter dated October 19, 2026.
Drugs@FDA
Novartis terminates Phase 2 iptacopan lupus nephritis trial after Part 1
The company ended the LNP023 study following completion of Part 1, citing strategic considerations, according to the trial's ClinicalTrials.gov record.
ClinicalTrials.gov
Crescent Biopharma details pipeline timelines for CR-001, CR-002 and CR-003
An October 15, 2026 8-K lays out trial progress and upcoming data readouts across Crescent's bispecific antibody and two ADC programs.
SEC filing
Edesa Biotech gets FDA clearance to add US sites to EB06 vitiligo trial
The company said its Phase 2 study of EB06 can now enroll patients in the United States, with topline data expected in the fourth quarter of 2027.
SEC filing
Novartis withdraws planned phase 2 retreatment study of ianalumab in ITP and wAIHA
The trial, meant to test a second course of ianalumab in patients who had previously responded, was withdrawn before enrolling, per its ClinicalTrials.gov record updated October 15, 2026.
ClinicalTrials.gov
FDA approves supplement 13 for Cosentyx, Novartis's secukinumab
The efficacy supplement for the 150mg injectable was approved on October 15, 2026, according to FDA records.
Drugs@FDA
OPKO Health agrees to sell lab testing assets to LabCorp for up to $872 million
BioReference Health will sell its clinical and anatomic pathology testing business, including the 4Kscore prostate cancer test, to Laboratory Corporation of America Holdings.
SEC filing
Eupraxia hits enrollment target in Phase 2b RESOLVE trial for EP-104GI
Eupraxia Pharmaceuticals enrolled and treated its 120th patient in the placebo-controlled portion of the RESOLVE trial for eosinophilic esophagitis, with interim data due in December 2026.
SEC filing
FDA approves new Evoxac capsule formulation for Cosette Pharmaceuticals
The agency cleared a Type 3 new dosage form application for Evoxac, an oral cevimeline hydrochloride capsule, with an approval letter dated October 19, 2026.
Drugs@FDA
FDA clears supplemental efficacy application for Genentech's Enspryng
The agency approved an eighth supplement to satralizumab's biologics license, according to FDA records dated October 15, 2026.
Drugs@FDA
Recursion prices $200M offering, reports Sanofi milestone and TUPELO, DAHLIA data
The company priced a 61.5 million share offering at $3.25 as Sanofi exercised an option on a first collaboration candidate and new REC-4881 and REC-1245 trial data emerged.
SEC filing (4)
Evofem amends note agreement with Adjuvant, pushing maturity to December 2026
The fifth amendment to Evofem Biosciences' 2020 Securities Purchase Agreement resets the payoff date for convertible notes held by Adjuvant and strips out certain covenants.
SEC filing
Alnylam's Phase 1 trial of ALN-4915 in healthy volunteers is active, not recruiting
Sanofi registers new RSV immunization survey; three prior Queensland studies also update
St. Jude posts results for CPX-351 pilot study in pediatric secondary myeloid neoplasms
FDA accepts Aquestive's Anaphylm NDA resubmission, sets March 2027 PDUFA date
The agency classified the resubmission as a Class 2 response, and Aquestive plans a Health Canada submission in the fourth quarter of 2026.
SEC filing
Tenax Therapeutics' LEVEL-2 Phase 3 trial of oral levosimendan in PH-HFpEF is active, not recruiting
Olema board member resigns, replacement named to two committees
Dr. Gorjan Hrustanovic stepped down from Olema Pharmaceuticals' board effective October 14, 2026, and Dr. Prakash Raman took over his committee seats.
SEC filing
Pfizer wins two FDA labeling supplements; obesity trial roster unchanged
Biohaven licenses IgG degrader portfolio to Ono Pharma for Asian markets
The deal covers lead candidate BHV-1300, in Phase 3 for Graves' disease, plus two follow-on degraders, with Biohaven set to receive up to $100 million near term.
SEC filing
Cidara's CD388 Phase 3 ANCHOR trial for flu prevention is recruiting, enrollment up to 10,000
Legend Biotech gets FDA IND clearance for in vivo CAR-T candidate LB2501
The clearance paves the way for a planned U.S. Phase 1/2 study of the CD19/CD20 dual-targeting in vivo CAR-T therapy in relapsed or refractory B-cell malignancies.
SEC filing
ALX Oncology swaps 13.35 million shares for pre-funded warrants in stockholder exchange
The company entered exchange agreements with Blackstone Annex Master Fund, RA Capital Healthcare Fund, and venBio Global Strategic Fund, set to settle October 15, 2026.
SEC filing
Vertex posts Phase 3 results for ELX/TEZ/IVA in CF infants 12 to 24 months
Anavex clears FDA hurdle for blarcamesine in Fragile X syndrome
The FDA has allowed Anavex's IND for blarcamesine in Fragile X syndrome to proceed, giving the company open INDs across all three of its core CNS indications.
SEC filing
Evotec names Dr. Joanna Holbrook as Chief Scientific Officer
The appointment to Evotec's Management Board takes effect November 1, 2026, bringing in a 25-year industry veteran to oversee scientific strategy.
SEC filing
Actinium names Matt David, M.D. as chief financial officer
Actinium Pharmaceuticals said Matt David, who previously served as CFO and chief business officer at CorMedix, began as CFO on October 14, 2026.
SEC filing
NeOnc adds First Abu Dhabi Bank executive Ali Alabedin to its board
The appointment, effective October 9, 2026, coincides with Abu Dhabi health authorities clearing an IND for NeOnc's NEO212 to support planned Phase 2 work in the UAE.
SEC filing
Aditxt subsidiary Ignite Proteomics ends business combination with Copley Acquisition Corp
The deal, entered in June 2026, was mutually terminated effective October 9, 2026, with all ancillary agreements also ending.
SEC filing
GSK registers large new Shingrix cardiovascular trial; DESTINY HES study update posted
Boehringer Ingelheim posts Brightline-2 brigimadlin results; BI 4060107 trial recruits
Tonix reports preliminary TONMYA revenue of $14.0M to $15.0M for Q3 2026
Tonix disclosed early quarterly figures ahead of final results, estimating cash of about $162.8 million as of September 30, 2026.
SEC filing
AbbVie adds John M. Carethers to board, expanding to 13 directors
AbbVie appointed Dr. John M. Carethers as a Class II director on October 14, 2026, according to an 8-K filed with the SEC.
SEC filing
Valion Bio's CDMO unit reports early data from LarmorBio NMR monitoring deal
Velocity Bioworks completed an initial feasibility test of LarmorBio's BioScan-NMR platform, less than six months after Valion secured exclusive rights to the technology.
SEC filing
Mustang Bio gets second 180-day window to fix Nasdaq bid price deficiency
Nasdaq granted the company until April 12, 2027 to lift its stock price back above $1.00 after it missed an earlier October 12 deadline.
SEC filing
Adlai Nortye signs trial deals with Lilly, Merck KGaA for AN4035-cetuximab study
The agreements provide free cetuximab supply for a Phase I trial combining Adlai Nortye's investigational ADC AN4035 with the EGFR antibody in RAS-addicted solid tumors.
SEC filing
Helus Pharma names ex-Intra-Cellular CMO Suresh Durgam to its board
The clinical-stage CNS drug developer moved its longtime scientific adviser onto the board as it pushes HLP003 through Phase 3 and HLP004 through Phase 2.
SEC filing
Biomerica board member Moatazedi to step down at December annual meeting
David Moatazedi told the board he will not seek re-election at Biomerica's December 11, 2026 annual stockholders meeting.
SEC filing
Ensho Therapeutics files Form D for equity offering of up to $15.6 million
The Delaware biotechnology company reported $7,281,948 sold toward a total offering of $15,604,179, with a first sale date of October 2, 2026.
SEC filing
United Therapeutics posts TETON-2 Phase 3 results for inhaled Tyvaso in IPF
Iambic Therapeutics prices IPO at $16 per share, lists on Nasdaq as IAM
The AI-driven drug discovery company is selling 9,375,000 shares to raise about $135 million for its HER2 inhibitor program and platform development.
SEC filing
FDA approves three generic drug applications, four submissions, across Amneal and ANI Pharms
Wednesday, October 14
Enliven Therapeutics adds Kristine Ball to board ahead of planned Phase 3 CML trial
The company appointed Ball, a biopharma executive with commercial-transition experience, as it prepares to start its pivotal relcobatinib trial before year-end 2026.
SEC filing
The company: Par Health Issues Voluntary Nationwide Recall of Argatroban Injection Due to the Presen
A record notice: the source is linked, and no summary was written because none passed the fact check.
FDA
Silo Pharma buys software assets from Larry King for stock
Silo Pharma issued 150,000 shares to Larry King under an October 13, 2026 asset purchase deal covering software and related intellectual property.
SEC filing
FDA approves supplement for Merck's Enflonsia (clesrovimab-cfor)
The agency's efficacy supplement for the injectable RSV antibody was approved with a status date of October 14, 2026.
Drugs@FDA
Lakefront sells preclinical CAR-T pipeline to Armed Cell Therapeutics
Lakefront gets €8 million upfront, up to $230 million in milestones, and royalties as it completes its cell therapy wind-down.
SEC filing
Longeveron's chief medical officer to step down October 14
Dr. Nataliya Agafonova notified Longeveron management on October 7, 2026 that she is resigning as Chief Medical Officer.
SEC filing
Lisata Therapeutics adds Tarsus eye care CFO Jeff Farrow to board
Farrow, who serves as CFO and chief strategy officer of Tarsus Pharmaceuticals, joins Lisata's Audit Committee as the board expands to eight members.
SEC filing